The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against Covid-19, a White House official said on April 15.
Moncef Slaoui, who served as chief scientist for the Operation Warp Speed response to the Covid-19 pandemic under former President Donald Trump, was fired as chairman of the board of directors of Galvani Bioelectronics following the “substantiation” of allegations of sexual harassment and inappropriate conduct.
Johnson & Johnson Chief Executive Officer Alex Gorsky told CNBC that people may need to get vaccinated against Covid-19 annually over the next several years, like seasonal flu shots.
Moderna Inc. proposed filling vials with additional doses of the Covid-19 vaccine to ease a crunch in manufacturing as the company approaches the manufacturing of almost a million doses a day.
Moderna Inc. asked the U.S. Food and Drug Administration for permission to fill the company’s Covid-19 vaccine vials with up to five additional doses to ease a crunch in manufacturing, CNBC reported.
Moderna started development on a booster to the company’s Covid-19 vaccine, which is hoped to work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
Hours after being sworn in as the 46th President of the United States, Joe Biden signed 10 executive orders aimed at combating the ongoing Covid-19 crisis.
Pfizer Chief Executive Officer Albert Bourla said his company supports Joe Biden’s $1.9 trillion coronavirus-focused plan that is intended to boost vaccination efforts and address the pandemic.
Moncef Slaoui, the GlaxoSmithKline vaccines veteran who has helmed the federal government’s Operation Warp Speed Covid-19 vaccine program, is stepping down from the role ahead of the inauguration of President-elect Joe Biden.
Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.